Clinical Trial Update: Safety and Efficacy Study of ADL5859 in Participants With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of ADL5859 in neuropathic pain associated with diabetic peripheral neuropathy; the trial is completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetic Peripheral Neuropathy
• Neuropathic Pain
• Peripheral Neuropathy

Drugs mentioned

• ADL5859

Snippet

Sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Conditions: Peripheral Neuropathy, Neuropathic Pain | Phase 2 | Status: COMPLETED | Results posted: 2015-07-01